SCHEMBL6402270

SCHEMBL6402270

CN1CCN(CCCNc2ccccc2N)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.50
KDM4E B2RXH2 1/20 0.47
HSD17B10 Q99714 1/20 0.47
SIGMAR1 Q99720 1/20 0.46
FGFR1 P11362 2/20 0.46
KDR P35968 2/20 0.46
RAD52 P43351 1/20 0.45
HRH3 Q9Y5N1 2/20 0.44
METAP2 P50579 1/20 0.43
BACE1 P56817 1/20 0.43
ADRA2C P18825 1/20 0.42
SRC P12931 2/20 0.42
SLC2A1 P11166 3/20 0.42
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
HTR7 P34969 1/20 0.42
HTR6 P50406 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879184 0.91 KAT2B (0.47) KMT2AKDM4EHSD17B10SIGMAR1ADRA2C
Hydrochloric Acid SCHEMBL3882917 0.89 KAT2B (0.46) KMT2AKDM4EHSD17B10SIGMAR1ADRA2C
SCHEMBL3874659 0.88 HRH3 (0.53) KDM4EHSD17B10HRH3BACE1
SCHEMBL11713412 0.86 HRH3 (0.56) HRH3BACE1
Hydrochloric Acid SCHEMBL3876019 0.86 HRH3 (0.52) KDM4EHSD17B10HRH3BACE1
SCHEMBL11710141 0.85 HRH3 (0.42) KMT2AKDM4EHSD17B10SIGMAR1RAD52
SCHEMBL7973929 0.84 POLB (0.54) KMT2AKDM4EHSD17B10SIGMAR1RAD52
SCHEMBL11195836 0.81 HTR2A (0.53) DRD2HTR2A
SCHEMBL11713319 0.80 POLB (0.48) KMT2AFGFR1KDRHRH3
Hydrochloric Acid SCHEMBL11196477 0.80 HTR2A (0.52) DRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050153978-A1 Medicaments GLAXO GROUP LIMITED (GB) 2005-07-14 US disclosed
EP-1487441-A2 BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-22 EP disclosed
WO-2003080125-A2 BENZIMIDAZOLES AND THEIR USE AS MITOGEN-ACTIVATED- AND RHO-KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-10-02 WO disclosed
US-4059584-A ANTIINFLAMMATORY PFIZER (US) 1977-11-22 US disclosed
US-4002623-A Anti-inflammatory 1-[3-(dialkylamino)propyl]-2-acylaminobenzimidazoles and 2-acylamino-3-[3-(dialkylamino)-propyl]imidazo[4,5-b]pyridines PFIZER INC. (US) 1977-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050153978-A1 Medicaments GRK1, ROCK1, GRK7 KMT2A 3764/4885KDM4E 2915/4885HSD17B10 4410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.